Overall Genedrive PLC (LON: GDR) reported a business and financial update for the six months to December 2017 in line with expectations Launch preparation of Genedrive® HCV test with partner Sysmex on track, expect sales to start coming through in CY2018 £1.3mln income from the ongoing collaboration with the US DoD, in line with expectations Discussions for the disposal of the Services business are in progress With £4.6mln of cash at end-2017, and given the company's expected cash burn, a capital raise in the next 12 months can't be ruled out Full financial results for the six months to December 2017 to be published on March 20th
18 Jan 2018
Genedrive - On Track to Launch the First CE-market Decentralised HCV Test
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Genedrive - On Track to Launch the First CE-market Decentralised HCV Test
Genedrive Plc (GDR:LON) | 3.4 0 0.0% | Mkt Cap: 4.67m
- Published:
18 Jan 2018 -
Author:
Dr. Riccardo Lowi -
Pages:
3
Overall Genedrive PLC (LON: GDR) reported a business and financial update for the six months to December 2017 in line with expectations Launch preparation of Genedrive® HCV test with partner Sysmex on track, expect sales to start coming through in CY2018 £1.3mln income from the ongoing collaboration with the US DoD, in line with expectations Discussions for the disposal of the Services business are in progress With £4.6mln of cash at end-2017, and given the company's expected cash burn, a capital raise in the next 12 months can't be ruled out Full financial results for the six months to December 2017 to be published on March 20th